



Institut Hospital del Mar
d'Investigacions Mèdiques

COLON MUTATION GENETIC TEST EXTENDED

The patent for the first test was obtained in 2013, and the detection kit was launched by the Belgian company Biocartis in 2014. In 2016, it has been expanded, with a new licence, to include newly-detected mutations.

Thanks to the agreement between IMIM and Biocartis these new biomarkers were incorporated and marketed as part of a unique panel of colon cancer markers using state-of-the-art detection platforms. These platforms allow the easy, quick and highly sensitive analysis of a series of tumour mutations and, consequently, doctors rapidly receive the data they need to decide the best personalised treatment for each patient. Incorporating the recently identified mutations to these platforms explains a further 10-15% of the resistance developed by the tumours. With this increase EGFR mutations become, along with RAS mutations, the most important causes of resistance to this drug group.

At a time when medicine is evolving towards diagnoses based on biomarker analysis, research into and improvement of these techniques are key. This new set of resistance mutations enables improved patient care for colon cancer sufferers who are receiving anti-EGFR therapy. It is a clear example of how in just a short time the results of a research project can be transferred to industry, in this case the Belgian multinational Biocartis, and which can be applied almost immediately to patients, improving and personalising colon cancer treatments.

Further information

<https://www.imim.cat/noticies/621/un-nou-test-genetic-millora-i-amplia-la-deteccio-de-les-mutacions-causants-de-la-resistencia-als-tractaments-de-cancer-de-colon>

www.biocartis.com